中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
4-[(4-甲氧基苯甲酰基)氨基]苯甲酸乙酯 | ethyl 4-(4-methoxybenzoylamino)benzoate | 100278-51-1 | C17H17NO4 | 299.326 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | 4-methoxy-N-[4-[(methylcarbamothioylamino)carbamoyl]phenyl]benzamide | 187274-33-5 | C17H18N4O3S | 358.421 |
—— | 4-[(4-methoxybenzoyl)amino]-N-[(E)-(4-methoxyphenyl)methylideneamino]benzamide | 100278-44-2 | C23H21N3O4 | 403.4 |
—— | p-(p-Methoxybenzamido)benzoic acid 2-(p-methylbenzylidene)hydrazide | 100278-46-4 | C23H21N3O3 | 387.4 |
—— | N-[4-[(ethylcarbamothioylamino)carbamoyl]phenyl]-4-methoxybenzamide | 187274-34-6 | C18H20N4O3S | 372.448 |
—— | N-[(E)-[4-(dimethylamino)phenyl]methylideneamino]-4-[(4-methoxybenzoyl)amino]benzamide | 100278-45-3 | C24H24N4O3 | 416.5 |
—— | p-(p-Methoxybenzamido)benzoic acid 2-cinnamylidenehydrazide | 100278-26-0 | C24H21N3O3 | 399.4 |
—— | N-{4-[2-(4-bromobenzylidene)hydrazinecarbonyl]phenyl}-4-methoxybenzamide | —— | C22H18BrN3O3 | 452.307 |
—— | 4-methoxy-N-[4-[(prop-2-enylcarbamothioylamino)carbamoyl]phenyl]benzamide | 187274-36-8 | C19H20N4O3S | 384.459 |
—— | 4-methoxy-N-[4-[(propylcarbamothioylamino)carbamoyl]phenyl]benzamide | 187274-35-7 | C19H22N4O3S | 386.475 |
—— | 4-methoxy-N-[4-[[(4-methylphenyl)carbamothioylamino]carbamoyl]phenyl]benzamide | 466690-15-3 | C23H22N4O3S | 434.519 |
—— | p-(p-Methoxybenzamido)benzoic acid 2-furfurylidenehydrazide | 100278-28-2 | C20H17N3O4 | 363.4 |
—— | 4-methoxy-N-[4-[[(4-methoxyphenyl)carbamothioylamino]carbamoyl]phenyl]benzamide | 466690-16-4 | C23H22N4O4S | 450.518 |
—— | N-[4-[(cyclohexylcarbamothioylamino)carbamoyl]phenyl]-4-methoxybenzamide | 187274-37-9 | C22H26N4O3S | 426.539 |
—— | p-(p-Methoxybenzamido)benzoic acid 2-veratrylidenehydrazide | 100278-37-3 | C24H23N3O5 | 433.5 |
—— | 4-[(4-methoxybenzoyl)amino]-N-[(E)-(5-nitro-2-furyl)methyleneamino]benzamide | —— | C20H16N4O6 | 408.37 |
In this study, a series of hydrazide-hydrazone derivatives (3a-3u) were synthesized and evaluated for their anticancer activitiesagainst prostate cancer cell line (PC-3), breast cancer cell line (MCF-7), colon cancer cell line (HT-29) and human umbilical vein endothelial cells (HUVEC) using MTT assay. In particular, compound 3h having a pyrrole ring was found to be the most potent derivative with IC50 = 1.32, 2.99, 1.71 μM against PC-3, MCF-7, HT-29 cancer cell lines respectively using paclitaxel as a standard compound. Furthermore, compound 3h was subjected to further biological studies such as caspase-3 activity and Annexin-V assay to evaluate their inhibitory potentials. The activity results displayed that compound 3h increased caspase-3 activation and the number of cells to early apoptosis. The additional studies like pharmacokinetics, bioavailability scores and drug-likeness properties were also evaluated. The in silico pharmacokinetics predictions displayed that the bioavailability of these compounds may be high.
In this study, thirteen phthalimide derivatives were designed and synthesized. All synthesized compounds were evaluated to determine their potential for inhibitory activities against females of the Caribbean fruit fly, Anastrepha suspensa (Loew) (Diptera: Tephritidae). These efforts led to the discovery of three compounds 4a, 4c, and 4d with potent insecticidal activity (LD50 range from 0.70 to 1.91 μg/fly). Among these compounds, 4a exhibited the highest inhibitory potency with 0.70 μg/fly. In addition, in silico models indicated that compound 4a is less toxic than phthalimide and other precursors. Therefore, our results suggest that 4a has strong potential as a candidate component for developing a novel environmentally friendly insecticide for control of pest fruit flies.